![]() |
||||
|
|
||||
|
|
||||
|
|
Testimony from a nurse to the Senate who became ill from Lupron.......From: andrea (anonymous@obgyn.net)Tue Oct 16 15:04:25 2007
These quotes are from the PDF that Maggie found of testimony of a nurse, Lynne Millican, to the Senate, who became ill from Lupron 10 years ago. I also spoke with Emily Page, the woman who started the Lupron petition, and she also believes there is a cover-up going on when it comes to Lupron. She sued TAP, but was given very little money, because her doctor denied her problems were caused by the Lupron. She is still very sick today. Please read these outtakes, and see what you think....falsifying 80% of info in 4 Lupron studies? That sounds like a cover-up to me.... pg 54: TAP has been declared a criminal enterprise based upon its scheme with physicians and billing fraud and kickbacks and they just paid the largest fine in history at the time, $875 million. pg 58: The internet posts of women identify the badgering, and coercion, and manipulation, and threats used to convince women into taking Lupron for a variety of indications—many refer to their doctor as trying to ‘‘shove it down [their] throat’’. pg 58: I would later learn that the director of this IVF clinic, Dr. Andrew Friedman, had been a lead Lupron investigator, had received numerous grants and funds from Lupron’s manufacturer, Takeda Abbott Pharmaceuticals (TAP), and had published extensively on Lupron. Dr. Friedman was ultimately found guilty of falsifying and fabricating approximately 80 percent of the data in four Lupron studies, two of which had been published and were subsequently retracted. Friedman had ‘‘altered and fabricated information in patient medical records, falsified research notes by changing dates and changing and adding text’’, and fabricated notes and fabricated patients for clinical visits that had not taken place. pg 61: The profoundly significant and despicable thefts (‘‘conversion’’, ‘‘sharing’’) of women’s ova and embryos by Drs. Ricardo Asch, Sergio Stone and Jose Balmaceda at the University of California at Irvine (Regents; Press; 1995) should be a serious reminder to the utter (and anesthetized) ease with which such menacing maneuvers can be executed. (And Dr. Asch had co-authored studies of Lupron, ‘‘which was kindly provided by Abbott’’ [Guerrero, 1993]). The contemptible violations of stealing women’s eggs and embryos should highlight the profitability of schemes to procure women’s eggs and embryos for use in research and/or covert ‘re-sale’. Dr. Asch reportedly ‘left his office daily with briefcase stuffed with thousands of dollars’. And attention should be directed to the drug protocol(s) used—medications administered ‘‘deliberately’’ ‘‘so there would be a surplus of eggs’’ (Challender, 1995). Who is exerting any oversight over the field of reproductivity? Who would exert oversight over therapeutic cloning—this same industry? pg 63: Women are told that Lupron will ‘‘shut down their system’’, allowing ‘‘control’’ over their system, and that the side effects are related to menopausal symptoms. But in fact, it was known prior to my ‘treatment’ with Lupron (but not disclosed to me) that Lupron causes a ‘‘hypophysectomy’’ (Holmes, 1988)—which, by definition, is ‘‘destruction or removal of the pituitary’’; and it was known (but not disclosed to me) that ‘‘sustained treatment with GnRH agonists most likely abolishes pituitary function’’ (Bischof, 1988). I would also later learn that in the original rat studies submitted to the FDA for Lupron’s initial approval of palliative prostate cancer, all rats at all doses developed pituitary adenomas (tumors)—and it was stated that ‘‘there is no obvious reason to suggest that the same process could not occur in humans’’ (NDA 19–010). pg 65: Published medical reports have noted the occurrence of abnormal human pregnancy outcomes associated with the use of Lupron—43.5 percent in one 1996 study (Karande, 1996). Another report, using the ‘long Lupron protocol’, showed a 38 percent abortion rate (Shanis, 1995), and a study of ‘low responders’ using Lupron showed a 66.6 percent spontaneous first trimester abortion rate (Droesch, 1989). In ‘healthy women undergoing ovarian stimulation’ using Lupron in another study, an- other 66.6 percent abortion rate was noted (Minaretzis, 1995). Another study’s title states ‘‘Exposure to [Lupron] in Early Pregnancy is Associated With High Pregnancy Wastage That Could be Related to the Length of Exposure’’ (Sasy, 1997). pg 69: The U.S. investigation of TAP’s billing practices revealed that a computer program given by TAP to many doctors in the country (some 10,000 urologists received gifts from TAP), which computated the amount of money per Lupron prescription the doctor could earn, also harbored a ‘secret key’—and in the event the secret computer program was in danger of discovery, a secret key was struck and !presto! all incriminating information disappeared. The first long-term follow-up of children who were accidentally exposed to GnRHa's was published in 1999, and revealed that 4 out of the 6 children studied had severe neurodevelopmental abnormalities (including seizure disorder). If that figure holds up in larger subsequent follow-up of children ... I would ask - do you think there is a problem here ... and what is the solution?' Archives of Ophthalmology, 2001, carried an article with a telling title:Ocular Anomalies Seen in Children Born After IVF'. On March 7, 2002 a new study was released indicating that the former 2-3% rate of major birth defects from IVF - a percentage always classified as consistent with the general population - was, in fact, in error. This study now found a 9% rate of major birth defects among IVF offspring. Will the percentage of birth defects from IVF continue to climb? http://www.stemcellresearch.org/testimony/complete_hearing-2006-03.pdf
|
|
Return to ![]()
Technical Problems: webmaster@obgyn.net
Last Updated: Wed Dec 2 04:01:36 2009
Women's Insurance Checklist from Auto Insurance Quote
home | medical professionals | women | industry | forums | international